14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ACRX ranks #13723 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

AcelRx Pharmaceuticals Stock Forecast NASDAQ:ACRX

$0.63 (1.87%)

Volume: 581k

Closed: Dec 08, 2021

Hollow Logo Score: -3.847

AcelRx Pharmaceuticals Stock Forecast

$0.63 (1.87%)

Volume: 581k

Closed: Dec 08, 2021

Score Hollow Logo -3.847
Which way will ACRX go? Request
Key Stats
Beta 1.18
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 41 and the stock is currently not being overbought or oversold

AcelRx Pharmaceuticals stock price ended on $0.63 on Wednesday after gaining 1.87%
(Updated on Dec 08, 2021)

Sell candidate since 2021-09-28 Loss -39.86%

The AcelRx Pharmaceuticals stock price gained 1.87% on the last trading day (Wednesday, 8th Dec 2021), rising from $0.61 to $0.63. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 6.31% from a day low at $0.60 to a day high of $0.64. The price has fallen in 6 of the last 10 days and is down by -5.08% for this period. Volume fell on the last day by -808 thousand shares and in total, 581 thousand shares were bought and sold for approximately $363.23 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -40.29% during the next 3 months and, with a 90% probability hold a price between $0.33 and $0.44 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, December 06, 2021, and so far it has risen 10.75%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The AcelRx Pharmaceuticals stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.77. On a fall, the stock will find some support from the short-term average at $0.61. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Support, Risk & Stop-loss

AcelRx Pharmaceuticals finds support from accumulated volume at $0.62 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0380 between high and low, or 6.31%. For the last week the stock has had a daily average volatility of 8.91%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is AcelRx Pharmaceuticals stock A Buy?

AcelRx Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.847

Predicted Opening Price for AcelRx Pharmaceuticals of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$0.62 $0.63 (Overvalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Aug 17, 2021 "HC Wainwright" gave "$7.00 - $5.00" rating for ACRX. The price target was changed from $1.12 to 4.3%.

Volatility and Risk
Daily Average Volatility: 8.91 %
Overall Risk: Very High High Medium Low Very Low
8.91 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $0.71
Price: $0.63
Support: $0.62

ACRX Insider Trading Show all Trades



Last 100 transactions
Buy: 4 613 923 | Sell: 248 625 (Shares)
Date Action Amount Person Type
Nov 20, 2021 Buy 30 000 Broadfoot Jill Marie Stock Option (Right to Receive)
Nov 20, 2021 Buy 15 000 Broadfoot Jill Marie Common Stock
Jun 17, 2021 Buy 10 000 Wan Mark A Common Stock
Jun 17, 2021 Buy 20 000 Wan Mark A Stock Option (Right to Buy)
Jun 17, 2021 Buy 10 000 Adams Adrian Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 4 613 923 | Sell: 248 625 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.66 5.60 %
0.65 3.27 %
0.64 1.84 %
Current price: 0.63
Support 0.61 -2.80 %
0.60 -4.23 %
0.58 -6.55 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.75 19.28 %
0.72 14.98 %
0.71 13.49 %
Current price 0.63
Support 0.62 -0.61%
0.61 -1.84%
0.56 -9.70%

Click to get the best stock tips daily for free!

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain in the United States. The company’s lead product candidates include ARX-04, a sufentanil sublingual tablet that is in Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings; and Zalviso, a sufentan... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE